We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Studies of Laser Ablation in Treatment of Primary Liver Carcinoma-Associated Portal Vein Tumor Thrombus.
- Authors
Baomu Sun; Ming Luo; Zhenghua Lu; Yan Meng; Shengbing Wu; Mengchao Wu
- Abstract
Objective: To explore the clinical values of laser ablation as a new treatment for portal vein tumor thrombus (PVTT). Methods: A total of 43 male patients with primary liver carcinoma (PLC)-associated PVTT were randomized into a laser ablation group and a radiotherapy group. The laser ablation group of 21 cases received direct percutaneous laser ablation under ultrasonographic guide, followed by direct injection into the portal vein with chemotherapy drugs including mitomycin C (MMC) and fluorouracil (5-Fu). The radiotherapy group of 22 cases was treated with X-ray in three-dimensional conformal radiotherapy (3D CRT) once a day for a total of 10 days course. After the treatment, all patients were followed for postoperative adverse reactions, changes of tumor thrombus, and survival time. Results: In comparison with the radiotherapy, laser ablation resulted in decreased postoperative complications such as limb fatigue, ascites, upper gastrointestinal ulcer, and bleeding. The overall remission rates (complete remission [CR] + partial remission [PR]) were 61.9% (13/21) and 31.8% (7/22) in the laser ablation and radiotherapy group, respectively, with a significant difference (P < .05). All cases in the laser group showed clinical improvement and the average survival time prolonged to greater than 19.5 months (P < .002). Conclusion: Percutaneous laser ablation to PVTT is an effective, safe, and simply procedure and has proven to offer significant clinical outcomes in the treatment of PLC-associated PVTT.
- Publication
Clinical & Applied Thrombosis/Hemostasis, 2010, Vol 16, Issue 6, p694
- ISSN
1076-0296
- Publication type
Article
- DOI
10.1177/1076029609336857